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Soluble CD23 as an effector of immune dysregulation in chronic uremia
and dialysis. Patients with chronic renal failure often present an
immunodeficiency state paradoxically exacerbated by hemodialysis and
associated with signs of T cell activation. The presence of circulating
monokines suggests that monocytes are also activated. Whether or not
this includes B cells is controversial, despite frequently abnormal
antibody responses. We thus investigated whether the soluble low-
affinity receptor for IgE (Fc,RII/CD23), recently identified as a marker
of B cell and monocyte activation and possibly involved in T cell
activation, was modulated by chronic renal failure and hemodialysis.
Relative to values in healthy individuals (N = 31), plasma concentra-
tions of soluble CD23 were significantly elevated in non-dialyzed
chronically uremic patients (N = 44), more elevated in patients on
peritoneal dialysis (N = 24), and most elevated in those on regular
hemodialysis (N 132), stabilizing after about six months. Soluble
CD23 levels were unmodified by the first dialysis session but rose
markedly during regular dialysis with cellulose or polysulfone mem-
branes, but not with polyacrilonitrile AN-69 membranes. Soluble CD23
levels correlated with levels of IgO, and those of tumor necrosis factor
a and interleukin-6, suggesting that increased sCD23 levels reflect
activation of B cells and monocytes, respectively. These findings
reinforce the view of soluble CD23 as a multi-functional receptor!
cytokine, and provide evidence that it might contribute to the immune
dysregulation associated with chronic renal failure and exacerbated by
hemodialysis.
Patients undergoing long-term intermittent hemodialysis for
end-stage renal disease often present a state of immunodefi-
ciency [reviewed in 1] manifested by increased susceptibility to
intracellular pathogens, such as mycobacteria [2], and to ma-
lignant tumors [3], together with anergy in cutaneous delayed
hypersensitivity tests [4], prolonged survival of skin allografts
[5], and defective responses to T cell-dependent antigens such
as influenza and hepatitis B vaccines [6, 7]. Interestingly,
phenotypic and functional signs of T cell activation are present
[8—10] together with elevated serum levels of the soluble IL-2
receptor (sIL-2 R) [11]. We have recently found increased
circulating levels of interleukin-l (IL-i), tumor necrosis factor a
(TNFa) and interleukin-6 (IL-6) suggestive of monocyte activa-
tion in these patients [12—14]. Intriguingly, both activated T
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cells and increased production of these cytokines are present in
previously non-dialyzed uremic patients [9, 12—14]. Great inter-
est has been focused on whether B cell activation and/or B
cell-derived molecules contribute to the acquired immunodefi-
ciency in patients with end-stage renal failure. Although pa-
tients on maintenance hemodialysis can develop abnormal
antibody responses, particularly IgE sensitization against the
ethylene oxide (EtO) used for sterilizing dialysis equipment [15,
16], the functional status of their B cells remains controversial
[1, 8, 17, 18].
CD23 was originally described as a 45-kDa surface glycoprotein
strongly expressed by Epstein-Barr virus-transformed lymphoid
cell lines, and was considered as a B cell-specific differentiation
marker [19]. It has now been cloned, and is identical to the
low-affinity receptor for IgE (FcRII) [20, 21]; its inducible form
is detectable in various cell types [22]. Because it contains a
proteolytic cleavage site, CD23 is readily split into soluble
fragments of 12, 25 and 32 to 35 kDa [23]. Besides B cells, only
monocytes and macrophages have been shown to release
soluble CD23 (sCD23) [22]. It is generally accepted that the 32
to 35 kDa soluble fragment of CD23, which is spontaneously
shed from the surface of EBV-transformed lymphoid blast cell
lines and activated B cells, retains the ability to bind IgE, and is
therefore one of the IgE binding factors [reviewed in 22].
The role of sCD23, originally thought to be restricted to IgE
regulation, has recently been re-evaluated. It now appears to
act as multi-functional receptor/lymphokine [24]. Indeed, CD23
controls the proliferation of B and T cells via a triangular
network involving IL-2 and IL-4 [25] and, in synergy with IL-l,
induces the differentiation of early thymocytes [26]. In addition,
as CD23 is spatially linked to HLA-DR, it might also be
involved in antigen presentation by monocyte-macrophages
[27].
This study was designed to determine whether sCD23 might
form a novel marker of B cell and/or monocyte activation,
acting as a costimulating factor in the T cell activation associ-
ated with chronic uremia and exacerbated by hemodialysis. In
view of the mechanisms involved in the release of sCD23, we
examined whether its circulating level was influenced by the
dialysis procedure, which induces exocytosis of proteases from
granulocytes [28] and can trigger massive production of reactive
oxygen species in whole blood, mainly via the ability of dialysis
membranes to activate complement [29, 30].
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Table 1. Patient characteristics
Peritoneal
No dialysis(N = 44)
dialysis(N = 24)
Hemodialysis(N = 132)
Male/female 26/18 19/5 59/73
Mean age years (range) 55 (16—83) 53 (18—83) 48 (16—89)
Primary renal disease
n (%)
Glomerulonephritis 13 (30%) 10 (42%) 33 (25%)
Interstitial nephritis 14 (32%) 3 (12%) 20 (15%)
Polycystic kidney 8 (18%) 2 (8%) 15 (11%)
disease
Other hereditary renal 2 (5%) 1 (4%) 7 (5%)
diseases
Angionephrosclerosis 5 (11%) 4 (4%) 6 (4%)
Other identified 0 0 23 (17%)
disordersa
Unclassified 2 (5%) 4 (4%) 28 (2 1%)
a Diabetes (7), lupus (3), cancer (3), vasculitis (3), amyloidosis (2),
myeloma (2), hemolytic uremic syndrome (2), cortical necrosis (1).
Methods
Study population
Two hundred patients with chronic renal failure were inves-
tigated with their informed consent. Forty-four patients had
never been dialyzed, of whom 22 who were tested just before
the beginning of hemodialysis therapy. Of the other 156 pa-
tients, 132 had been on regular hemodialysis thrice weekly for
between 1 month and 16 years (mean SD, 46.9 16.2 months)
and 24 were on chronic ambulatory peritoneal dialysis (CAPD).
The characteristics of the three patient groups at entry into the
study are given in Table 1. Thirty-one healthy adult volunteers
recruited among blood donors of the Centre de Transfusion
Sanguine de 1'Hôpital Necker served as controls.
Dialysis conditions
Patients were dialyzed in four to five hour sessions with
single-use hollow-fiber dialyzers (sterilized with EtO and thor-
oughly rinsed with 2 liters of sterile pyrogen-free saline prior to
use). Dialyzers were equipped with cellulose (Cuprophan,
Fresenius, Bad Hombourg, Germany) or cellulose acetate
membranes (Baxter Laboratories, Illinois, USA) for all the
initial dialysis sessions. For the patients on regular hemodialy-
sis, cellulose membranes were used in 91 cases, polyacriloni-
true AN-69 membranes (Hospal, Meyzieu, France) in 25 and
polysulfone membranes (Fresenius) in 16. The dialysate had a
standard ionic composition and bicarbonate was used as the
buffer substrate. All patients were treated in the same center
(Necker's Hospital), except in the groups of patients treated
with polyacrilonitrile or polysulfone in which 10 cases of each
group were regularly treated at the Centre Edouard Rist.
Study protocol
All the patients were tested just prior to a dialysis session.
Seventeen first-dialysis patients and 116 patients undergoing
long-term (>6 months) hemodialysis (cellulose membranes in
65 cases, polyacrilonitrile AN-69 membranes in 25 and polysul-
fone membranes in 16) were also tested at the end of the
session. In addition, sCD23 was also measured in 14 patients
hemodialyzed with cellulose membranes. 15 minutes after start
of dialysis, that is, at the time of maximum leukopenia and
activation of complement and phagocyte oxidative metabolism
[29—31].
Plasma preparation
Blood samples (5 to 10 ml) were collected in heparinized
tubes (Liquemine® Roche, Paris, France, 10 U/mI of blood).
Following centrifugation (600 g x 10 mm) plasma was separated
into 500 d aliquots and stored at —20°C. Assays were carried
out on duplicate plasma samples thawed only once.
Soluble CD23 determination
Plasma sCD23 levels were determined using an immunora-
diometric assay with monoclonal antibodies which recognize 25
to 37 kDa sCD23 fragments; this assay recently been marketed
as a kit (Medgenix, Fleurus) gives results in sCD23 U/mI.
According to results obtained with a purified preparation of 25
kDa recombinant sCD23 fragment kindly provided by Dr.
Mossalayi [26], one unit of sCD23 corresponds to 1.25 ng of
sCD23.
Within- and between-assay coefficients of variation were less
than 5 percent.
Other receptors and cytokines
Commercial enzyme-linked immunosorbent assays (ELISA)
were used to measure IL-6 and TNFa (Medgenix), sIL-2R
(Immunotech, Luminy, Marseille, France) and IL-4 (R & D
systems, Minneapolis, Minnesota, USA) following the techni-
cal protocols given by the manufacturers.
Other plasma substances
Total IgE and EtO-specific IgE were measured using specific
kits (CAP system Pharmacia, Division Diagnostics, St Quentin
en Yvelines, France); IgG and 1gM were measured with specific
reagents (Behring Diagnostic, Rueil Malmaison) using an auto-
mated immunonephelometric method (Nephelemeter BNA,
Behring). Acute-phase proteins including C-reactive protein,
a2-macroglobulin, a-1-anti-proteinase and haptoglobulin were
also measured by means of immunonephelometry.
In vitro study of the effect of dialysis membranes on sCD23
The ability of dialysis membranes to bind sCD23 was inves-
tigated using a device supplied by Dr. R. Deppish (Gambro,
Hechingen, Germany). It consists of 24-well plastic Petri dishes
(1.93 cm2), the bottoms of which are covered with either
cellulose (cuprophan type) or polyacrilonitrile AN-69 dialysis
membrane sections. Each well was rinsed twice with sterile
saline (1 ml, 20 mm at 37°C) then once with RPMI 1640 medium
supplemented with 1% human AB serum (1 ml, 30 mm at 37°C)
just before use.
In a first set of experiments, normal plasma (0.5 ml) supple-
mented with 15 U/mI of sCD23 was exposed to dialysis mem-
branes or to plastic (controls) for various times. The plasma was
then removed and immediately tested for sCD23 content by
immunoassay. In a second set of experiments, pooled plasma
from hemodialysis or peritoneal dialysis patients was exposed
for two hours to dialysis membranes or plastic before testing.
The results are reported as % of sCD23 adsorption, defined as
follows:
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(1 concentration of sCD23 (U/mi) in plasma exposed to membranes
Concentration of sCD23 (U/mi) in plasma exposed to plastic
)< 100
Presentation of results and statistical analyses
The possible influence of body fluid shifts on sCD23 levels in
hemodialyzed patients was checked by comparing variations of
sCD23 during the session to those of body weight and the total
plasma-protein concentration. As no significant difference was
found between these two modes of evaluating hemoconcentra-
tion, we corrected post-dialysis values for the total plasma-
protein concentration.
Plasma samples were tested in duplicate and the results for
each group are expressed as means SEM. Student's two-tailed
t-test (paired or unpaired as appropriate) was used to compare
continuous variables after assessing the normality of their
distribution. The chi-squared test was used to compare propor-
tions and the Spearman rank (rb) test was used to identify
correlations between variables. Differences were considered
significant when the P value was 0.05 or less.
Results
Plas,na levels of sCD23 in non-dialyzed and dialyzed patients
Plasma levels of sCD23 were significantly higher in the 44
non-dialyzed uremic patients than in the 31 healthy subjects (3.0
0.3 vs. 1.7 0.03 U/mi, P < 0.001), but were significantly
lower than in the 24 peritoneal dialysis patients (5.0 0,58
U/ml, P < 0.001) and the 132 regular hemodialysis patients (8.6
0.44 U/mi, P < 0.0001). sCD23 levels exceeded 10 U/ml in 37
(28%) hemodialysis patients compared to only one (2%) non-
dialyzed patient and one (4%) patient on pentoneal dialysis(P < 0.0001; Fig. 1).
Influence of the degree of renal failure and the duration of
dialysis on sCD23 levels
In the group of non-dialyzed patients, sCD23 levels increased
moderately with the severity of renal failure (Table 2). A
negative correlation was found between sCD23 levels and
creatinine clearance calculated according to Cockcroft and
Gault [32] (r =
—0.49, P < 0.02).
Among the patients regularly dialyzed with cellulose mem-
branes (N = 91), those treated for six months or less had
significantly higher predialysis sCD23 levels than the non-
dialyzed patients (P < 0.001), but significantly lower levels than
the patients treated for six months or more (P < 0.02). Beyond
six months, the mean predialysis sCD23 levels were similar
regardless of the total duration of dialysis (Table 2).
Influence of the dialysis procedure on sCD23 levels
The influence of the dialysis procedure on sCD23 levels was
compared in uremic patients undergoing initial dialysis and in
long-term (6 months) hemodialyzed patients treated with
cellulose membranes (Fig. 2). sCD23 levels were similar at the
beginning (3.6 0.6 U/mi) and end of the initial dialysis session
(3.5 0.47 U/mi), but both pre- and postdialysis levels in-
creased significantly in the regular dialysis patients (8.2 0.6
and 11.5 0.9 U/mi, respectively,P<0.001). A slight increase
was apparent two hours after the start of the dialysis session but
not after 15 minutes (data not shown).
Fig. I. Plasma levels of sCD23 in chronic renal failure and dialysis.
Plasma levels of sCD23 in 44 non-dialyzed uremic (UR) patients, 25
patients on chronic ambulatory peritoneal dialysis (CAPD), 132 patients
on regular hemodialysis (HD) and 31 healthy subjects (controls).
Plasma sCD23 levels were significantly increased in UR, CAPD and HD
patients relative to the controls (P < 0.001). The differences between
the UR and the CAPD or HD patients were also highly significant (P <
0.001).
N Mean sCD23 levels 5EM
Healthy subjects 31 1.70 0.03
Patients P < 0.001
No dialysis (total cases) 44 3.00 0.30
Moderate renal failure 12 2.19 0.08
(Ccr: 70—30 mI/mm) P < 0.05
Severe renal failure 10 2.54 0.12
(Ccr: 30—10 mI/mm)
Predialysis 22 3.60 0.57
Peritoneal dialysis 24 5.00 0.58
P < 0.02
P < 0.001
Hemodialysis (total cases) 91 7.76 0.54 P < 0.0001
<6 months 26 5.15 0.47
P < 0.02
P < 0.001
6—24 months 30 8.00 0.96
2—5 years 15 9.45 1.60
>5 years 20 9.50 1.28
Influence of dialysis membrane type on sCD23 levels
The influence of the type of dialysis membrane on the
increase in sCD23 levels was investigated in 106 patients who
had been dialyzed for at least six months with the same
membrane type (Table 3). Pre- and postdialysis levels of sCD23
C')
CM
C-)
U)
25
20
15
10
5
0
Controls UR CAPD HO
Table 2. Influence of the grade of renal failure and the duration of
dialysis on plasma levels of sCD23
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Fig. 2. Influence of the dialysis procedure on plasma levels of sCD23.
Plasma levels of sCD23 in 17 first-dialysis uremic (UR) patients and 57
long-term (6 months) hemodialysis (HD) patients dialyzed with cellu-
lose membranes, at the start (ts) and at the end (te) of dialysis sessions.
sCD23 levels did not differ significantly at the end of the session in the
UR patients but were significantly increased in the HD patients (P <
0.001).
were significantly higher with cellulose membranes and polysul-
fone membranes than with polyacrilonitrile AN-69 membranes
(P < 0.001), and the mean increments observed during the
dialysis session were also higher (P < 0.001).
Influence of clinical features on sCD23 levels
In an attempt to determine the respective parts played by
uremia-related factors and dialysis, the influence of various
Table 3. Influence of dialysis membrane type on plasma levels of
sCD23
sCD23 levels during dialysis sessions
(mean SEM)
N Start End
Cellulose 65 8.81 0.70
P<0.0l
13.25 1.21
P<0.001
Polyacrilonitrile AN-69 25 5.50 0.50
P < 0.001
6.70 0.60a
P < 0.001
Polysulfone 16 10.29 1.59 17.22 3.14a
a p < 0.01 versus values at the start of the session (paired t-test).
Differences between polysulfone and cellulose membranes were not
statistically significant regardless of the time before and after the
dialysis session.
Table 4. Influence of the original nephropathy on plasma levels of
sCD23
Mean sCD23 levels SEM
Non-dialyzed
(N= 44)
Hemodialyzeda
(N= 65)
Glomerulonephritis
Interstitial nephritis
Polycystic kidney disease
Nephroangiosclerosis
Other identified disorders
Unclassified
3.13 0.33 (14)
3.03 0.30 (13)
2.08 0.11 (8)'
3.10 0.50 (5)
None
3.20 0.90 (2)
8.80 1.34 (18)
9.84 1.92 (12)
6.61 1.25 (18)
8.40 (1)
8.50 1.10 (11)
10.03 2.50 (9)
Differences between non-dialyzed and hemodialyzed groups are
statistically significant (P < 0.0001).
a Patients dialyzed with cellulose membranes for at least 6 months
b P < 0.02 vs. glomerulonephritis and interstitial nephritis
clinical and biological factors on predialysis sCD23 levels was
compared in patients tested just before their first dialysis
session (N = 22) and in patients who had been dialyzed for six
months or more with the same type (cellulose) of membrane
(N = 65).
Age and sex. Neither age nor sex had an influence on sCD23
levels in first-dialysis and long-term dialysis patients (data not
shown).
Type of nephropathy and residual diuresis. Patients with
polycystic kidney disease had lower sCD23 levels than those
with other types of nephropathy; however, differences were
significant (P = 0.02) only in the group of non-dialyzed patients
(Table 4). Regardless of the type of nephropathy, no difference
in mean sCD23 levels was found between 22 hemodialysis
patients with little (200 ml) or no diuresis (8.1 0.9 U/mI) and
12 patients with residual diuresis of 500 ml or more (8.8 0.4
U/mi).
Infections and chronic inflammation. Mean sCD23 levels
were slightly higher in long-term hemodialysis patients with
bacterial infections (N = 13, 10.9 1.6 U/ml), parasitic
diseases (N = 8, 11 1.7 U/mI) and severe dialysis arthropathy
with p2-microglobulin amyloidosis (N = 6, 10.1 2.9), but
differences with the other patients (N = 38, 8.1 0.7 U/mI)
were not statistically significant. Plasma levels of acute-phase
proteins were significantly elevated in some of the hemodialysis
patients, for example, C-reactive protein (27% of cases), hap-
toglobin (16%), and al-anti-protease (8%), while a2-macroglob-
ulin levels were within the normal range or decreased (12%); no
40
35
30
25
20
15
10
5
0
ts te
UR
ts
HD
te
-
& 
ci
) 
.
 
UI
 
0 
0 
0 
0 
0 
882 Descamps-Latscha et a!: Soluble CD23 in chronic uremia and dialysis
Discussion
0
a.
0
Co
.0(0
0)
0
Co
0
Normal plasma CAPD plasma
+sCD23
HD plasma
Fig. 3. In vitro study of adsorption of sCD23 on cellulose and poly-
acrilonitrile dialysis membranes. Plasma (0.5 ml) from a normal indi-
vidual supplemented with 15 U/ml of sCD23 and plasma from HD or
CAPD patients containing high levels of sCD23 (respectively 22.5 and
8.5 U/ml) were exposed to 24-well plastic Petri dishes covered with
cuprophan (0, 0) or polyacrilonitrile AN-69 (•,) membranes for
four hours. The insert shows kinetics of sCD23 adsorption in normal
plasma supplemented with 15 U/ml (results of a typical experiment).
correlation was found between the respective levels of these
acute-phase proteins and those of sCD23.
Relationships between sCD23 and immunocompetent cell
activation
T cells. Plasma levels of sIL-2 R were above the normal range
(< 50 to 100 pM) in both non-dialyzed (280 17 pM) and
hemodialyzed patients (293 80 pM), but no correlation was
found with sCD23 levels. IL-4 plasma levels were below the
detection limit (<50 pg/mI) except in two patients, both of
whom had severe parasitic infections: IL-4 levels were 250 and
4,500 pg'ml, and sCD23 levels 9 and 11 U/mI, respectively.
B cells. There was a correlation between plasma levels of
sCD23 and those of IgG (r = 0.48, P < 0.01). Only one patient
had elevated plasma levels of total IgE (900 KU/liter); another
had detectable EtO-specific IgE (4.5 KU/liter) but a normal
level of total IgE (7 KU/liter); both patients had high levels of
sCD23 (respectively 15.7 and 14.4 U/ml).
Monocytes. Plasma levels of TNFa and IL-6 were above the
normal range (<5 pg/mi) in both the non-dialyzed (26 2.4 and
35 8 pg/ml, respectively) and peritoneal dialysis patients (50
3.5 and 21 2.3 pg/ml, respectively). Plasma levels of sCD23
correlated with those of TNFa (r5 = 0.55, P < 0.001) and IL-6(r 0.48, P < 0.002).
In vitro study of the effect of dialysis membranes on sCD23
plasma levels
Figure 3 compares the absorption capacity of cellulose (cu-
prophan) and polyacrilonitrile membranes for sCD23. Both
normal plasma supplemented with exogenous sCD23 and
pooled plasma from hemodialysis or peritoneal dialysis patients
containing more than 15 U of sCD23/ml showed a 20 to 25%
reduction in sCD23 levels following a four hour contact with
polyacrilonitrile AN-69, but not with cellulose membranes. This
absorption capacity was already maximal two hours after the
start of incubation (Fig. 3 insert).
We present evidence that increased circulating levels of
sCD23 are found in chronic uremic patients according to the
degree of renal failure, and that regular hemodialysis with
cellulose and polysulfone membranes is associated with a
further increase in sCD23 levels, which reach a plateau around
the sixth month.
Few clinical studies on sCD23 have been reported. The
values in our uremic patients are within the range reported in
patients with hairy-cell leukemia [33] or allergic/parasitic dis-
eases [34], but far below the levels observed in patients with B
cell-derived chronic lymphocytic leukemia [35].
The positive correlation in the group of non-dialyzed patients
between sCD23 plasma levels and the degree of renal impair-
ment, together with the significant increase in sCD23 observed
up to the sixth month of hemodialysis, would suggest a passive
accumulation of sCD23 due to its reduced urinary elimination.
Little is known of the clearance of sCD23 from blood. Although
sCD23 has been reported to be present in urine [33], we failed
to detect it in urine samples from healthy subjects (data not
shown). Moreover, sCD23 levels were not higher in hemodia-
lyzed patients with little or no urinary output than in those with
significant residual diuresis, thus suggesting that reduced uri-
nary excretion alone does not explain accumulation of sCD23.
However, this does not entirely rule out the possibility that
decreased renal function is involved in this setting, either
directly or indirectly via the accumulation of non-dialyzable
uremic toxins [36] which could contribute to triggering sCD23
production.
To our knowledge, CD23 expression in the kidney has not
been reported, although the concept of intrarenal immune
activation is now well documented in certain types of glomer-
ulonephritis [37, 38] and interstitial nephntis [39]. Interestingly,
the non-dialyzed patients with these types of nephropathy had
significantly higher levels of circulating sCD23 than those with
polycystic kidney disease, a feature that did not correlate with
residual diuresis (data not shown). The possibility that accumu-
lation of sCD23 in cysts might contribute to lowering plasma
levels in these patients is supported by the demonstration that
cytokines are present in cyst fluid [40].
With regard to the systemic origin of sCD23, increased
plasma levels could reflect an activation of B cells. The corre-
lation we found between sCD23 and IgG plasma levels also
favors B cells as a source of sCD23. Apart from activated B
cells, eosinophils also express CD23 [41], but the monocyte
sCD23 levels were also closely related to those of TNFa and/or
IL-6 in non-hemodialyzed patients. This strongly supports a
contribution of activated monocytes to the increased plasma
levels of sCD23. The presence of elevated levels of sIL-2R in
both the non-dialyzed and dialyzed uremic patients confirms
previous reports [42] and further supports the concept that T
cells are activated [1, 8—10] in these patients. Such activated T
cells could contribute to the overexpression of CD23 on B cells,
either by direct contact or secondary to the release of IL-4 [43].
The fact that we could not detect IL-4 does not exclude the
possibility that its biologically active form may cause enhanced
CD23 expression.
One remarkable finding was that, in contrast to first dialysis
sessions, long-term dialysis using cellulose membranes induced
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a significant rise in plasma sCD23 levels. This is in keeping with
previous studies of the respective influence of uremia and
hemodialysis on phagocyte oxidative metabolism [44] and in-
flammatory cytokines [12—14]. Likewise, elevated pre- and
postdialysis sCD23 levels were observed in patients undergoing
regular dialysis with polysulfone membranes, while such an
increase was not observed with polyacrilonitrile AN-69 mem-
branes. Given the easy cleavage of CD23 into its soluble
fragments, it is tempting to explain the effects of the different
membranes by differences in their capacity to induce via
complement activation the generation of reactive oxygen spe-
cies [30] or elastase [45], all of which would be expected to
induce the release of sCD23. However, the complement acti-
vating potential of polysulfone membranes has been reported as
intermediary between that of cellulose and polyacrilonitrile
[46], whereas sCD23 levels in patients treated with polysulfone
membrane were as high as or even higher than those in patients
treated with cellulose. Alternatively, the lower sCD23 levels in
patients dialyzed with polyacrilonitrile AN-69 membranes may
have been due to the known capacity of this material to adsorb
endogenous proteins; indeed, this appears highly probable on
the basis of our results obtained in vitro.
The main role attributed to sCD23 is the regulation of IgE
production, although no simple correlation exists between
sCD23 and IgE levels in patients with allergy [22, 43]. Interest-
ingly, a possible dysregulation of IgE synthesis has been
reported in hemodialysis patients, who often show abnormal
IgE levels that are attributed mainly to EtO sensitization [15,
16]. However, contrary to these reports, total IgE levels were
within the normal range in most of our patients, and EtO-
specific IgE was only detected in one case. It is noteworthy
that, in our center, dialyzers are very thoroughly rinsed after
EtO sterilization. Because sCD23 levels were nevertheless
increased in most of our patients, this increase may reflect an
origin other than ETO sensitization.
Regarding the possible role of sCD23 in the immune dysfunc-
tion associated with chronic renal failure, it may well reflect the
T cell activation process observed in these patients. Indeed
IL-i, which is increased in this setting [12, 14], plays a major
role in the regulation of IL-2 production by T cells but requires
an additional activation signal to induce the expression of IL-2
receptors. sCD23, which has recently been shown to be mito-
genic for T cells in synergy with IL-i [26], could serve as such
a signal. Moreover, there is a bilateral co-regulation between
CD23 and the IL-2 R complex, in that triggering of sCD23
enhances IL-2R expression, and IL-2 enhances the expression
of CD23 [43]. sCD23 could thus contribute to the over-con-
sumption of IL-2 by its receptor, leading to the abnormally low
bioavaiiability of this pivotal cytokine in the immune response,
and to the resulting immunodeficiency of chronic uremic pa-
tients.
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